Interleukin (IL)-13 as a Marker in Pediatrics Asthma

Rush University Medical Center19 enrolled

Overview

Asthma is a very common childhood chronic illness and is generally more severe in African Americans. The investigators attempted to determine whether a specific immune marker is associated with lung function and asthma severity.

This study examined the relationship between Interleukin (IL)-13 from phytohemagglutinin-activated polymorphonuclear blood cells and asthma severity, lung function (measured as FEV1%), and total serum IgE levels in African American children with clinically diagnosed asthma

Study Type

OBSERVATIONAL

Enrollment

Conditions

Asthma

Eligibility

Sex: ALLMin age: 8 YearsMax age: 15 Years

Medical Language ↔ Plain English

Inclusion Criteria: * African-American race, born in the U.S. * Age 8-15 years * Clinical diagnosis of asthma * Subject is able to understand and follow verbal instructions in English Exclusion Criteria: * Asthma exacerbation in the 4 weeks preceding the research visit * Oral/IV steroid use in the 4 weeks preceding the research visit * Upper or lower respiratory tract infection in the 4 weeks preceding the research visit * Antibiotic use in the 4 weeks preceding the research visit * Use of a short-acting bronchodilator during the 6 hours prior to spirometry (lung function testing) * Use of a long-acting bronchodilator during the 12 hours prior to spirometry (lung function testing)

Locations (1)

Rush University Medical Center; Clinic: University Consultants in Allergy and Immunology

Chicago, Illinois, United States

Outcomes

Primary Outcomes

Interleukin-13 from phytohemagglutinin activated peripheral blood mononuclear cells

Time frame: 7 months (from the start to completion of study. The blood was drawn at the one and only visit for each subject)

Secondary Outcomes

Lung function measured by percent predicted forced expiratory volume in the first second (FEV1%)

Time frame: 7 months (from the start to completion of study, but FEV1% was measured at the one and only visit for each subject)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.